--- title: "Aadi Bioscience (NASDAQ:AADI) Stock Price Down 2.5% - Here's What Happened" type: "News" locale: "en" url: "https://longbridge.com/en/news/283091716.md" description: "Aadi Bioscience (NASDAQ:AADI) shares fell 2.5% to $3.90 during mid-day trading, with a trading volume of 316,496 shares, up 21% from the average. The stock's 50-day moving average is $3.37, and its market cap is $96.32 million. Aadi Bioscience focuses on developing precision medicines for genomically defined cancers, with its lead product candidate being fimepinostat. Analysts currently rate the stock as a Hold, but suggest other stocks may be better investments." datetime: "2026-04-17T04:53:56.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/283091716.md) - [en](https://longbridge.com/en/news/283091716.md) - [zh-HK](https://longbridge.com/zh-HK/news/283091716.md) --- # Aadi Bioscience (NASDAQ:AADI) Stock Price Down 2.5% - Here's What Happened Aadi Bioscience, Inc. (NASDAQ:AADI - Get Free Report)'s share price dropped 2.5% during mid-day trading on Thursday . The company traded as low as $3.74 and last traded at $3.90. Approximately 316,496 shares changed hands during mid-day trading, an increase of 21% from the average daily volume of 261,100 shares. The stock had previously closed at $4.00. Get **Aadi Bioscience** alerts: ## Aadi Bioscience Stock Performance The stock has a 50-day simple moving average of $3.37 and a two-hundred day simple moving average of $2.74. The firm has a market cap of $96.32 million, a PE ratio of -1.71 and a beta of 0.68. ## Aadi Bioscience Company Profile (Get Free Report) Aadi Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for genomically defined cancers. Headquartered in Redwood City, California, Aadi Bioscience was founded in 2012 and went public in 2019 on the Nasdaq Stock Market under the ticker AADI. The company's research strategy centers on identifying molecular drivers of tumor growth and designing small-molecule inhibitors that target these pathways. The company's lead product candidate, fimepinostat (CUDC-907), is a novel dual inhibitor of histone deacetylase (HDAC) and phosphatidylinositol 3-kinase (PI3K). ## See Also - Five stocks we like better than Aadi Bioscience _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Aadi Bioscience Right Now? Before you consider Aadi Bioscience, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aadi Bioscience wasn't on the list. While Aadi Bioscience currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [AADI.US](https://longbridge.com/en/quote/AADI.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) ## Related News & Research - [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md) - [Enanta Pharma's RSV Bet And Immunology Ambitions](https://longbridge.com/en/news/286895623.md) - [BeOne Wins First-in-Class U.S. FDA Nod for BCL2 Drug in Relapsed Mantle Cell Lymphoma](https://longbridge.com/en/news/286330888.md) - [BeOne Medicines Wins Conditional FDA Nod For Cancer Drug In Rare Blood Cancer](https://longbridge.com/en/news/286453582.md) - [Eton Pharmaceuticals Adds Another 2026 Launch As It Secures U.S. Rights To IMPAVIDO](https://longbridge.com/en/news/287025596.md)